Literature DB >> 1348043

Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

P Leinekugel1, S Michel, E Conzelmann, K Sandhoff.   

Abstract

A previously suggested model for the correlation between residual activity of a lysosomal enzyme and the turnover rate of its substrate(s) has been extended to a discussion of substrate accumulation rates in individual cells and whole organs. With these considerations, much of the observed variability in age of onset and clinical phenotype, as well as the phenomenon of pseudo-deficiency, can be understood as the consequences of small differences in the residual activity of the affected enzyme. In order to experimentally verify the basic assumptions on which this model rests, studies were performed in cell culture. The radiolabeled substrates ganglioside GM2 and sulfatide were added to cultures of skin fibroblasts with different activities of beta-hexosaminidase A or arylsulfatase A, respectively, and their uptake and turnover measured. In both series of experiments, the correlation between residual enzyme activity and the turnover rate of the substrate was essentially as predicted: degradation increased steeply with residual activity, to reach the control level at a residual activity of approximately 10-15% of normal. All cells with an activity above this critical threshold had a normal turnover. Comparison of the results of these feeding studies with the clinical status of the donor of each cell line basically confirmed our notions but also revealed the limitations of the cell culture approach.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348043     DOI: 10.1007/bf00219337

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  35 in total

1.  Adult (chronic) GM2 gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship.

Authors:  I Rapin; K Suzuki; K Suzuki; M P Valsamis
Journal:  Arch Neurol       Date:  1976-02

2.  Probable metachromatic leukodystrophy/pseudodeficiency compound heterozygote at the arylsulfatase A locus with neurological and psychiatric symptomatology.

Authors:  C Hohenschutz; W Friedl; K H Schlör; A Waheed; E Conzelmann; K Sandhoff; P Propping
Journal:  Am J Med Genet       Date:  1988-09

3.  Lysogangliosides: synthesis and use in preparing labeled gangliosides.

Authors:  G Schwarzmann; K Sandhoff
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  Assay for cerebroside sulfate (sulfatide) sulfatase in cultured skin fibroblasts with the natural activator protein.

Authors:  M Lee-Vaupel; E Conzelmann
Journal:  Clin Chim Acta       Date:  1987-09-15       Impact factor: 3.786

5.  A simple chromogenic assay for arylsulfatase A.

Authors:  M Lee-Vaupel; E Conzelmann
Journal:  Clin Chim Acta       Date:  1987-04-30       Impact factor: 3.786

6.  Hexosaminidase A deficiency in adults.

Authors:  R Navon; Z Argov; A Frisch
Journal:  Am J Med Genet       Date:  1986-05

7.  Preparation of GM1 ganglioside molecular species having homogeneous fatty acid and long chain base moieties.

Authors:  S Sonnino; G Kirschner; R Ghidoni; D Acquotti; G Tettamanti
Journal:  J Lipid Res       Date:  1985-02       Impact factor: 5.922

8.  Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects.

Authors:  S Sonderfeld; E Conzelmann; G Schwarzmann; J Burg; U Hinrichs; K Sandhoff
Journal:  Eur J Biochem       Date:  1985-06-03

9.  A simple and novel method for tritium labeling of gangliosides and other sphingolipids.

Authors:  G Schwarzmann
Journal:  Biochim Biophys Acta       Date:  1978-04-28
View more
  98 in total

1.  4th Symposium on Probing Disorders of the White Matter. Abstracts.

Authors: 
Journal:  J Mol Neurosci       Date:  1999-06       Impact factor: 3.444

2.  Role of beta Arg211 in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D Vocadlo; S Withers; D Mahuran
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

Review 3.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

4.  Supply-side and trickle-down therapy.

Authors:  G A Grabowski
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

5.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).

Authors:  Joe T R Clarke; Don J Mahuran; Swati Sathe; Edwin H Kolodny; Brigitte A Rigat; Julian A Raiman; Michael B Tropak
Journal:  Mol Genet Metab       Date:  2010-09-17       Impact factor: 4.797

6.  Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.

Authors:  Y Liu; A Hoffmann; A Grinberg; H Westphal; M P McDonald; K M Miller; J N Crawley; K Sandhoff; K Suzuki; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

7.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

Authors:  Susan D Orwig; Yun Lei Tan; Neil P Grimster; Zhanqian Yu; Evan T Powers; Jeffery W Kelly; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-11-14       Impact factor: 3.162

8.  Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.

Authors:  U H Schueler; T Kolter; C R Kaneski; G C Zirzow; K Sandhoff; R O Brady
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 9.  Metachromatic leukodystrophy: molecular genetics and an animal model.

Authors:  V Gieselmann; U Matzner; B Hess; R Lüllmann-Rauch; R Coenen; D Hartmann; R D'Hooge; P DeDeyn; G Nagels
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 10.  Glycosphingolipid degradation and animal models of GM2-gangliosidoses.

Authors:  T Kolter; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.